Search Results - "Lefvert, A. K."

Polymorphisms in the CTLA‐4 gene and inhibitor development in patients with severe hemophilia A by ASTERMARK, J., WANG, X., OLDENBURG, J., BERNTORP, E., LEFVERT, A.‐K.

“…See also Santagostino E. Can the genetic profile predict inhibitor development in hemophilia A? This issue, pp 261-2…”
Get full text

Two SNPs in the promoter region of the CTLA‐4 gene affect binding of transcription factors and are associated with human myasthenia gravis by Wang, XB, Pirskanen, R., Giscombe, R., Lefvert, A. K.

“… Objectives.  The molecular mechanisms underlying the regulation of the CD152 (CTLA‐4) gene are largely unknown. Two single nucleotide polymorphisms (SNPs)…”
Get full text

Antibodies Against Cardiolipin and Oxidatively Modified LDL in 50-Year-Old Men Predict Myocardial Infarction by Wu, Ruihua, Nityanand, Soniya, Berglund, Lars, Lithell, Hans, Holm, Goran, Lefvert, Ann Kari

“…Autoantibodies against oxidatively modified low-density lipoproteins (oxLDL) and cardiolipin occur in patients with vascular diseases, including…”
Get full text

Allelic polymorphisms in the repeat and promoter regions of the interleukin‐4 gene and malaria severity in Ghanaian children by GYAN, B. A., GOKA, B., CVETKOVIC, J. T., KURTZHALS, J. L., ADABAYERI, V., PERLMANN, H., LEFVERT, A.‐K., AKANMORI, B. D., TROYE‐BLOMBERG, M.

“…SUMMARY Immunoglobulin E has been associated with severe malaria suggesting a regulatory role for interleukin (IL)‐4 and/or IgE in the pathogenesis of severe…”
Get full text

A CTLA-4 gene polymorphism at position −318 in the promoter region affects the expression of protein by Wang, X B, Zhao, X, Giscombe, R, Lefvert, A K

“…CTLA-4 is an important negative regulator of the immune system. The regulation of the CTLA-4 gene (Ctla-4) transcription is poorly understood. A single…”
Get full text

Patients With Early-Onset Peripheral Vascular Disease Have Increased Levels of Autoantibodies Against Oxidized LDL by Bergmark, C, de Faire, U, Lefvert, A.K

“…Oxidative modification of LDL has been proposed as an early and crucial step in the development of atherosclerosis, and antibodies against such modified LDL…”
Get full text

The soluble forms of CD28, CD86 and CTLA‐4 constitute possible immunological markers in patients with abdominal aortic aneurysm by Sakthivel, P., Shively, V., Kakoulidou, M., Pearce, W., Lefvert, A. K.

“… Objective.  The T cell co‐stimulatory factors CD28 and CTLA‐4 and their ligands CD80 and CD86 occur as receptors on T cells and antigen‐presenting cells and…”
Get full text

Characterization of the expanded T‐cell populations in patients with Wegener's granulomatosis by GISCOMBE, R., WANG, X. B., KAKOULIDOU, M., LEFVERT, A. K.

“… Objectives.  Wegener's granulomatosis (WG) is a chronic inflammatory disease characterized by granulomatosis inflammation, systemic vasculitis and…”
Get full text

A clinical and immunological study of a myasthenia gravis patient treated with infliximab by Kakoulidou, M., Bjelak, S., Pirskanen, R., Lefvert, A. K.

“…Objectives –  To measure clinical and immunological parameters in a patient with myasthenia gravis (MG) treated with antibodies against tumour necrosis…”
Get full text

Human Soluble CD80 is Generated by Alternative Splicing, and Recombinant Soluble CD80 Binds to CD28 and CD152 Influencing T-cell Activation by Kakoulidou, M, Giscombe, R, Zhao, X, Lefvert, A.K, Wang, X

“…CD80 is a costimulatory factor mainly expressed on the surface of activated monocytes, B cells and dendritic cells. In this study, we demonstrate that 24% of…”
Get full text

Treatment of a patient with myasthenia gravis using antibodies against CD25 by Kakoulidou, M., Pirskanen-Matell, R., Lefvert, A. K.

“…Objectives –  To measure clinical and immunological parameters in a patient with myasthenia gravis (MG) treated with antibodies against CD25 (basiliximab,…”
Get full text

Expression of OX40 (CD134) on CD4+ T‐cells from patients with myasthenia gravis by Xiaoyan, Zhao, Pirskanen, R., Malmstrom, V., Lefvert, A. K.

“…Summary Myasthenia gravis (MG) is commonly regarded as the prototype of an antibody‐mediated, organ‐specific autoimmune disease. Antibodies against the…”
Get full text

Expression of CTLA‐4 by Human Monocytes by Wang, X.‐B., Giscombe, R., Yan, Z., Heiden, T., Xu, D., Lefvert, A. K.

“…Cytotoxic T lymphocyte‐associated molecule‐4 (CTLA‐4) is a receptor present on T cells that plays a critical role in the downregulation of antigen‐activated…”
Get full text

Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study by Lindberg, C., Andersen, O., Lefvert, A. K.

“…Objectives – To evaluate the efficacy and safety of one single intravenous methylprednisolone (IVMP) pulse therapy in myasthenia gravis. Material and methods –…”
Get full text

Increased levels of autoantibodies against copper‐oxidized low density lipoprotein, malondialdehyde‐modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis by Cvetkovic, J. T., Wållberg‐Jonsson, S., Ahmed, E., Rantapää‐Dahlqvist, S., Lefvert, A. K.

“…Objectives. To analyse the association of autoantibodies against cardiolipin (CL) and oxidized low density lipoproteins [copper‐oxidized low density…”
Get full text

β2 Adrenoceptor gene single nucleotide polymorphisms are associated with rheumatoid arthritis in northern Sweden by Xu, B-Y, Ärlehag, L, Rantapää-Dahlquist, S-B, Lefvert, A K

“…Background: β2 Adrenoceptor (β2-AR) represents a link between the sympathetic nervous system and the immune system, and may be involved in human rheumatoid…”
Get full text

Circulating CD4+CD25+ and CD4+CD25– T Cells in Myasthenia Gravis and in Relation to Thymectomy by Huang, Y.‐M., Pirskanen, R., Giscombe, R., Link, H., Lefvert, A.‐K.

“…Studies in experimental animal models of human autoimmune diseases have revealed that CD4+CD25+ T regulatory (Tr) cells are of thymic origin and have…”
Get full text

Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL by WU, R., LEFVERT, A. K.

“…SUMMARY Circulating antibodies against oxLDL are present in several inflammatory and autoimmune conditions. Such antibodies are also present in patients with…”
Get full text

Regulation of Surface and Intracellular Expression of CTLA‐4 on Human Peripheral T Cells by Wang, X.‐B., Zheng, C.‐Y., Giscombe, R., Lefvert, A. K.

“…Cytotoxic T‐lymphocyte‐associated antigen (CTLA‐4) is an important downregulator of T‐cell activation. In order to analyze the expression and regulation of…”
Get full text

Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients by Ragnhammar, P, Friesen, H J, Frödin, J E, Lefvert, A K, Hassan, M, Osterborg, A, Mellstedt, H

“…The pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), induction of anti-GM-CSF antibodies, and clinical…”
Get full text